CEREVEL ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cerevel Therapeutics Holdings, Inc. and Encourages Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. for allegedly misleading investors regarding the acquisition interest from AbbVie, which impacted the stock price during the class period from October 11, 2023, to August 1, 2024 [1][3]. Summary by Sections Lawsuit Details - The lawsuit is filed in the United States District Court for the District of Delaware on behalf of all individuals and entities who purchased Cerevel securities during the specified class period [1]. - Investors have until June 3, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. Allegations Against Cerevel - The complaint alleges that Cerevel's offering documents and public statements omitted material facts about AbbVie's interest in acquiring Cerevel at a price significantly higher than the $22.81 per share offering price, which artificially deflated the stock price until the merger announcement [3]. - It is claimed that Bain, Cerevel's controlling shareholder, acquired shares at an artificially depressed price while possessing nonpublic information about AbbVie's interest [3]. - On December 6, 2023, Cerevel announced that AbbVie agreed to acquire the company for$45 per share, resulting in Bain receiving over $120 million in windfall profits from shares acquired at the lower offering price [3]. Impact on Investors - The action seeks to recover damages for investors who held shares as of the January 8, 2024, record date and were harmed by the allegedly false and misleading statements in Cerevel's January 18, 2024, proxy statement [4]. - The proxy statement is alleged to have misled investors regarding the true nature and timing of AbbVie's interest in Cerevel [4].